Chemokine regulation of atherosclerosis
暂无分享,去创建一个
[1] T. Lagerweij,et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.
[2] Christian Weber,et al. Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[3] Y. Sheikine,et al. Can CXCL16 be linked to coronary vascular disease? We still know too little … , 2006 .
[4] P. V. van Riel,et al. Can CXCL16 be linked to coronary vascular disease? Comment on the article by Sheikine et al. , 2006, Atherosclerosis.
[5] G. Hansson,et al. T Cells in Atherogenesis: For Better or For Worse? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[6] A. Hamsten,et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. , 2006, Atherosclerosis.
[7] S. Reddy,et al. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention , 2006, Nature Clinical Practice Cardiovascular Medicine.
[8] D. Patel,et al. CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[9] P. Murphy,et al. Oxidized Lipid-Driven Chemokine Receptor Switch, CCR2 to CX3CR1, Mediates Adhesion of Human Macrophages to Coronary Artery Smooth Muscle Cells Through a Peroxisome Proliferator-Activated Receptor γ–Dependent Pathway , 2006, Circulation.
[10] N. Bresolin,et al. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease , 2006, Neuroscience Letters.
[11] I. Charo,et al. Targeted Disruption of the Scavenger Receptor and Chemokine CXCL16 Accelerates Atherosclerosis , 2006, Circulation.
[12] Peter Libby,et al. The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.
[13] J. Mehta,et al. Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. , 2006, Biochemical and biophysical research communications.
[14] K. Moore,et al. Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.
[15] Shigeyoshi Itohara,et al. Effect of MMP-2 Deficiency on Atherosclerotic Lesion Formation in ApoE-Deficient Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[16] R. Terkeltaub,et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. , 2006, The American journal of pathology.
[17] F. Tacke,et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Ye. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. , 2006, Cardiovascular research.
[19] B. Banas,et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. , 2005, Atherosclerosis.
[20] P. Tobias,et al. Modulation of atherosclerosis in mice by Toll-like receptor 2. , 2005, The Journal of clinical investigation.
[21] H. Shin,et al. CXCR3 polymorphisms associated with risk of asthma. , 2005, Biochemical and biophysical research communications.
[22] K. Rakesh,et al. Cytokines and growth factors involved in apoptosis and proliferation of vascular smooth muscle cells. , 2005, International immunopharmacology.
[23] J. Hirschhorn,et al. CCL2 Polymorphisms Are Associated With Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study , 2005, Circulation.
[24] F. Mach,et al. Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo , 2005, Circulation.
[25] R. Schnabel,et al. Genetic Analysis of the Interleukin-18 System Highlights the Role of the Interleukin-18 Gene in Cardiovascular Disease , 2005, Circulation.
[26] D. Ramji,et al. Interferon-g and atherosclerosis : Pro-or anti-atherogenic ? , 2005 .
[27] S. Anker,et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis , 2005, Journal of Molecular Medicine.
[28] A. Hamsten,et al. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR‐PSOX gene , 2005, Journal of internal medicine.
[29] O. Migita,et al. Association of a haplotype block spanning SDAD1 gene and CXC chemokine genes with allergic rhinitis. , 2005, The Journal of allergy and clinical immunology.
[30] A. Hajeer,et al. Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet's disease. , 2005, The Journal of rheumatology.
[31] L. Norgren,et al. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. , 2004, Biochemical and biophysical research communications.
[32] D. Teupser,et al. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[33] JanNilsson,et al. Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice , 2004 .
[34] L. Hovgaard,et al. Inhibition of Tumor Necrosis Factor-&agr; Reduces Atherosclerosis in Apolipoprotein E Knockout Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[35] E. Fisher,et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Sakoda,et al. Critical Roles of CXC Chemokine Ligand 16/Scavenger Receptor that Binds Phosphatidylserine and Oxidized Lipoprotein in the Pathogenesis of Both Acute and Adoptive Transfer Experimental Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.
[37] W. März,et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. , 2004, European heart journal.
[38] D. Broide,et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. , 2004, The Journal of clinical investigation.
[39] S. Akira,et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] Knud Erik Pedersen,et al. Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study , 2004, Circulation.
[41] F. Ohsuzu,et al. Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[42] M. Biondi,et al. Internal Carotid Artery Occlusive Disease and Polymorphisms of Fractalkine Receptor CX3CR1: A Genetic Risk Factor , 2004, Stroke.
[43] Frédéric Pincet,et al. Enhanced Adhesive Capacities of the Naturally Occurring Ile249–Met280 Variant of the Chemokine Receptor CX3CR1* , 2004, Journal of Biological Chemistry.
[44] U. Hedin,et al. CXCL16/SR-PSOX Is an Interferon-&ggr;–Regulated Chemokine and Scavenger Receptor Expressed in Atherosclerotic Lesions , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[45] A. Luttun,et al. Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.
[46] P. Dempsey,et al. A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 , 2004, The Journal of Immunology.
[47] K. Moore,et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.
[48] J. Fallon,et al. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. , 2004, Blood.
[49] F. Mach,et al. Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.
[50] T. Kita,et al. Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.
[51] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[52] P. Verpillat,et al. Association of the Toll-Like Receptor 4 Gene Asp299Gly Polymorphism With Acute Coronary Events , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[53] D. Greaves,et al. Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1) , 2003, Circulation.
[54] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[55] K. Egashira,et al. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases , 2003, Expert review of cardiovascular therapy.
[56] P. Tipping,et al. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. , 2003, The American journal of pathology.
[57] F. Fahrenholz,et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. , 2003, Blood.
[58] J. Drabek,et al. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. , 2003, Immunology letters.
[59] M. Taubman,et al. Chemokine Receptors in Vascular Smooth Muscle , 2003, Microcirculation.
[60] S. Akira,et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. , 2003, Cardiovascular research.
[61] I. Charo,et al. Chemokine Receptor 2 (CCR2) in Atherosclerosis, Infectious Diseases, and Regulation of T‐Cell Polarization , 2003, Microcirculation.
[62] P. Eriksson,et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. , 2003, Journal of the American College of Cardiology.
[63] C. Weber,et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age , 2003, Journal of Molecular Medicine.
[64] R. D'Agostino,et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. , 2003, The Journal of clinical investigation.
[65] N. Maeda,et al. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. , 2003, Atherosclerosis.
[66] N. Maeda,et al. Transplantation of Monocyte CC-Chemokine Receptor 2-Deficient Bone Marrow Into ApoE3-Leiden Mice Inhibits Atherogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[67] K. Egashira. Molecular Mechanisms Mediating Inflammation in Vascular Disease: Special Reference to Monocyte Chemoattractant Protein-1 , 2003, Hypertension.
[68] P. Debré,et al. Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.
[69] E. Antman,et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.
[70] I. Charo,et al. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.
[71] G. Cooke,et al. Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.
[72] V. Fuster,et al. Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging , 2002, Circulation.
[73] B. McManus,et al. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[74] D. Rader,et al. Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[75] M. Biondi,et al. Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Gene Promoter Polymorphisms Are Associated With Carotid Artery Stenosis , 2002, Stroke.
[76] D. Niederacher,et al. C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, codon 469). A risk factor for coronary heart disease and myocardial infarction. , 2002, International journal of cardiology.
[77] A. Daugherty,et al. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[78] P. Murphy. International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.
[79] M. Daemen,et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[80] J. Badimón,et al. CCR2 Deficiency Decreases Intimal Hyperplasia After Arterial Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[81] Yong-wen Qin,et al. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. , 2002, Cardiovascular research.
[82] 笹岡 大史. Polymorphisms in the platelet-endothelial cell adhesion molecule-1 (PECAM-1) gene, Asn563Ser and Gly670Arg, associated with myocardial infarction in the Japanese , 2002 .
[83] T. Kita,et al. Expression of Scavenger Receptor for Phosphatidylserine and Oxidized Lipoprotein (SR‐PSOX) in Human Atheroma , 2001, Annals of the New York Academy of Sciences.
[84] A. Kimura,et al. Polymorphisms in the Platelet‐Endothelial Cell Adhesion Molecule‐1 (PECAM‐1) Gene, Asn563Ser and Gly670Arg, Associated with Myocardial Infarction in the Japanese , 2001, Annals of the New York Academy of Sciences.
[85] E. Fisher,et al. Elevating High-Density Lipoprotein Cholesterol in Apolipoprotein E—Deficient Mice Remodels Advanced Atherosclerotic Lesions by Decreasing Macrophage and Increasing Smooth Muscle Cell Content , 2001, Circulation.
[86] B. Rollins. Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. , 2001, The Journal of clinical investigation.
[87] Steffen Jung,et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. , 2001, The Journal of clinical investigation.
[88] Masashi Komeda,et al. Expression of SR-PSOX, a Novel Cell-Surface Scavenger Receptor for Phosphatidylserine and Oxidized LDL in Human Atherosclerotic Lesions , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[89] C. Blobel,et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.
[90] S. Reddy,et al. Increased Transcription of IL-8 in Endothelial Cells Is Differentially Regulated by TNF-&agr; and Oxidized Phospholipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[91] Z. Fayad,et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. , 2001, Journal of vascular surgery.
[92] Z. Prohászka,et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. , 2001, Atherosclerosis.
[93] A. Quyyumi,et al. Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.
[94] V. Álvarez,et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction , 2001, Genes and Immunity.
[95] C. Kataoka,et al. New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E-Knockout Mice , 2001, Circulation.
[96] D. Soler,et al. Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.
[97] P. Debré,et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.
[98] D. Grobbee,et al. Homozygosity for 807 T Polymorphism in α2 Subunit of Platelet α2β1 Is Associated With Increased Risk of Cardiovascular Mortality in High-Risk Women , 2000 .
[99] Andrew C. Li,et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. , 2000, The Journal of clinical investigation.
[100] M. Koschinsky,et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. , 2000, Circulation.
[101] Y. Chao,et al. Infectious Agents Are Not Necessary for Murine Atherogenesis , 2000, The Journal of experimental medicine.
[102] P. Groot,et al. Localisation of mRNA for JE/MCP-1 and Its Receptor CCR2 in Atherosclerotic Lesions of the ApoE Knockout Mouse , 2000, Journal of Vascular Research.
[103] Weixin Zhao,et al. Human Vascular Smooth Muscle Cells Possess Functional CCR5* , 2000, The Journal of Biological Chemistry.
[104] U. Wahn,et al. Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.
[105] P. Libby,et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.
[106] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[107] C. Kessler,et al. The 2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin 2β1 Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients , 1999 .
[108] G. Baumann,et al. Functional Characterization of Atherosclerosis-Associated Ser128Arg and Leu554Phe E-Selectin Mutations , 1999, Biological chemistry.
[109] B. Rollins,et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[110] C. Iwai,et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. , 1999, Circulation.
[111] O. Quehenberger,et al. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. , 1999, Journal of lipid research.
[112] K Fukutake,et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[113] B. Rollins,et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.
[114] N. Camp,et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. , 1999, Circulation.
[115] B. Lämmle,et al. Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study , 1999, The Lancet.
[116] B. Rollins,et al. Monocyte chemoattractant protein-1. , 1999, Chemical immunology.
[117] O. Quehenberger,et al. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[118] I. Charo,et al. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.
[119] P. Libby,et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.
[120] D. Arveiler,et al. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. , 1998, Human molecular genetics.
[121] A. Roach,et al. Human vascular smooth muscle cells express receptors for CC chemokines. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[122] R. Terkeltaub,et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.
[123] Robert V Farese,et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.
[124] T. Schall,et al. Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.
[125] B. Rollins,et al. In vivo properties of monocyte chemoattractant protein‐1 , 1997, Journal of leukocyte biology.
[126] A. Tall,et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.
[127] J. Farber. Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.
[128] Wei Wang,et al. A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.
[129] P. Huie,et al. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[130] P. Tipping,et al. Interleukin-8 production by macrophages from atheromatous plaques. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[131] A. Henney,et al. Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.
[132] B. Rollins. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. , 1996, Molecular medicine today.
[133] R. Warnke,et al. RANTES chemokine expression in diseased and normal human tissues. , 1996, Cytokine.
[134] S M Schwartz,et al. The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.
[135] F. Neumann,et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. , 1995, Circulation.
[136] D. Taub,et al. Modulation of IL‐8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL‐8 , 1995, Journal of leukocyte biology.
[137] S. Murakami,et al. Expression of both types of human interleukin‐8 receptors on mature neutrophils, monocytes, and natural killer cells , 1995, Journal of leukocyte biology.
[138] L. F. Kolakowski,et al. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. , 1994, The Journal of biological chemistry.
[139] M. Kendall,et al. The oxidation hypothesis of atherosclerosis , 1994, The Lancet.
[140] G. Baumann,et al. E-selectin polymorphism and atherosclerosis: an association study. , 1994, Human molecular genetics.
[141] T. Yue,et al. Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. , 1994, Circulation research.
[142] S. Coughlin,et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.
[143] D. Steinberg,et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[144] R. Ross,et al. The role of endothelial injury and platelet and macrophage interactions in atherosclerosis , 1984, Circulation.
[145] R. Ross,et al. ENDOTHELIAL INJURY: BLOOD‐VESSEL WALL INTERACTIONS * , 1982, Annals of the New York Academy of Sciences.